P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In

 

News Categories

 

 

 

Report: HONDA Patients (Hypertensive, Obese, Non-Compliant, Diabetic, and Asthmatics) Drive Health Care Costs

HONDA therapies forecast to be among highest-selling drugs from 2012 to 2019 (September 24)

Decision Resources, a research and advisory firm located in Burlington, Mass., finds that the top 20% of costliest patients in the U.S. are responsible for more than 80% of total health care costs and that the top 1% of costliest patients are responsible for more than 20% of all health care expenditures. The HONDA patient population (hypertensive, obese, non-compliant, diabetic, and asthmatics) in the U.S. is of significant interest as a driver of health care costs as these patients concurrently have multiple complex comorbidities that significantly increase the risk for cardiovascular events and diabetic complications.

The report finds that the U.S. HONDA population will double from 2 million prevalent cases in 2012 to more than 4 million cases in 2022. In addition, therapies that are used to treat HONDA patients are forecast to be among the highest-selling and fastest-growing drugs from 2012 to 2019. Globally, the cardiovascular market was the highest-selling therapy area in 2012, with more than $99 billion in worldwide sales, and the metabolic market will be the fastest-growing therapy area over the next several years, increasing from nearly $54 billion in 2012 to more than $85 billion in 2019, according to the report.

The new findings also indicate that there is a significant opportunity for the development of safe and efficacious obesity therapies that can elicit at least 10% weight loss, owing to the large patient population and the dearth of competing therapies. The regulatory and reimbursement environments are both improving after more than a decade, during which time no new obesity drugs were approved in the U.S. Owing to the launch of new therapies, obesity drug sales are expected to show 51% annual growth in the U.S. from 2012 to 2016.

Source: Decision Resources; September 24, 2013.

More stories